Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders
Nicole M. Fisher
Mabel Seto
Craig W. Lindsley1,2 
Colleen M. Niswender- 1Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, United States
- 2Department of Chemistry, Vanderbilt University, Nashville, TN, United States
- 3Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, United States
A Corrigendum on
Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental
Disorders
by Fisher, N.M., Seto,M., Lindsley, C. W., and Niswender, C.M. (2018). Front.Mol. Neurosci. 11:387. doi: 10.3389/fnmol.2018.00387
In the original article, there was a mistake in Figure 1 as published. The chirality of L-AP4 and LSP1-2111 was incorrect. pEC50 values have also been corrected for LSP1-2111 in Table 1. The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Figure 1. Current tool compounds used to study mGlu7.
Table 1. Summary of current tool compounds used to study mGlu7.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Abe, M., Seto, M., Gogliotti, R. G., Loch, M. T., Bollinger, K. A., Chang, S., et al. (2017). Discovery of VU6005649, a CNS penetrant mGlu7/8 receptor PAM derived from a series of Pyrazolo[1,5-a]pyrimidines. ACS Med. Chem. Lett. 8, 1110–1115. doi: 10.1021/acsmedchemlett.7b00317
Acher, F., Pin, J.-P., Goudet, C., Eschalier, A., Busserolles, J., Rigault, D., et al. (2012). Hypophosphorous Acid Derivatives Having Antihyperalgic Activity and Biological Applications Thereof . US Patent 9212196B2. Paris: Universite Paris Descartes.
Gee, C. E., Peterlik, D., Neuhäuser, C., Bouhelal, R., Kaupmann, K., Laue, G., et al. (2014). Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior. J. Biol. Chem. 289, 10975–10987. doi: 10.1074/jbc.M113.542654
Goudet, C., Vilar, B., Courtiol, T., Deltheil, T., Bessiron, T., Brabet, I., et al. (2012). A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 26, 1682–1693. doi: 10.1096/fj.11-195941
Jalan-Sakrikar, N., Field, J. R., Klar, R., Mattmann, M. E., Gregory, K. J., Zamorano, R., et al. (2014). Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. ACS Chem. Neurosci. 5, 1221–1237. doi: 10.1021/cn500153z
Kalinichev, M., Le Poul, E., Boléa, C., Girard, F., Campo, B., Fonsi, M., et al. (2014). Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. J. Pharmacol. Exp. Ther. 350, 495–505. doi: 10.1124/jpet.114.214437
Kingston, A. E., Ornstein, P. L., Wright, R. A., Johnson, B. G., Mayne, N. G., Burnett, J. P., et al. (1998). LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 37, 1–12. doi: 10.1016/S0028-3908(97)00191-3
Le Poul, E., Boléa, C., Girard, F., Poli, S., Charvin, D., Campo, B., et al. (2012). A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 343, 167–177. doi: 10.1124/jpet.112.196063
Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic, S., et al. (2005). A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 18712–18717. doi: 10.1073/pnas.0508063102
Niswender, C. M., Johnson, K. A., Miller, N. R., Ayala, J. E., Luo, Q., Williams, R., et al. (2010). Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol. Pharmacol. 77, 459–468. doi: 10.1124/mol.109.058768
Reed, C. W., McGowan, K. M., Spearing, P. K., Stansley, B. J., Roenfanz, H. F., Engers, D. W., et al. (2017). VU6010608, a novel mGlu7 NAM from a series of N-(2-(1H-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides. ACS Med. Chem. Lett. 8, 1326–1330. doi: 10.1021/acsmedchemlett.7b00429
Selvam, C., Lemasson, I. A., Brabet, I., Oueslati, N., Karaman, B., Cabaye, A., et al. (2018). Increased potency and selectivity for group III metabotropic glutamate receptor agonists binding at dual sites. J. Med. Chem. 61, 1969–1989. doi: 10.1021/acs.jmedchem.7b01438
Suzuki, G., Tsukamoto, N., Fushiki, H., Kawagishi, A., Nakamura, M., Kurihara, H., et al. (2007). In Vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists. J. Pharmacol. Exp. Ther. 323, 147–156. doi: 10.1124/jpet.107.124701
Keywords: Neurodevelopmental disorder, ASD, Rett syndrome, mGlu7, GRM7, allosteric modulator
Citation: Fisher NM, Seto M, Lindsley CW and Niswender CM (2018) Corrigendum: Metabotropic Glutamate Receptor 7: A New Therapeutic Target in Neurodevelopmental Disorders. Front. Mol. Neurosci. 11:444. doi: 10.3389/fnmol.2018.00444
Received: 05 November 2018; Accepted: 19 November 2018;
Published: 14 December 2018.
Copyright © 2018 Fisher, Seto, Lindsley and Niswender. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Colleen M. Niswender, Colleen.niswender@vanderbilt.edu
†These authors have contributed equally to this work